MoonLake Immunotherapeutics — Director's Dealing 2024

Feb 17, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MoonLake Immunotherapeutics (MLTX)
CIK: 0001821586
Period of Report: 2024-02-14

Reporting Person: Reich Kristian (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-14	Class A ordinary shares, par value $0.0001 per share	S	10000	$62.42	Disposed	3017483	Indirect
2024-02-14	Class A ordinary shares, par value $0.0001 per share	S	10000	$62.43	Disposed	130071	Direct
2024-02-15	Class A ordinary shares, par value $0.0001 per share	S	10000	$60.17	Disposed	3007483	Indirect
2024-02-15	Class A ordinary shares, par value $0.0001 per share	S	10000	$60.16	Disposed	120071	Direct
2024-02-16	Class A ordinary shares, par value $0.0001 per share	S	10000	$60.15	Disposed	2997483	Indirect
2024-02-16	Class A ordinary shares, par value $0.0001 per share	S	10000	$60.15	Disposed	110071	Direct

Footnotes

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.10 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F6: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.18 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F7: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F8: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.